health_text_en

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Novavax, Inc. (Nasdaq: NVAX), […]

thaipr.net

21 ธ.ค. 64

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA) has…

thaipr.net

21 ธ.ค. 64

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute […]

thaipr.net

20 ธ.ค. 64

Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study

Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy […]

thaipr.net

16 ธ.ค. 64

Argon Medical Devices, Inc. Acquires Matrex Mold and Tool, Inc.

Argon Medical Devices, Inc., a leading manufacturer of medical devices for interventional procedures, announced the acquisition of Wisconsin-based Matrex Mold and Tool, Inc., a custom mold manufacturer for plastic injection molding. Matrex produces metal injection production and prototype molds for the medical device, residential, and automotive industries, and has done so since 1985. Argon was a […]

thaipr.net

15 ธ.ค. 64

Regional tuberculosis forum shines spotlight on innovation and collaboration driving progress toward ending tuberculosis in Asia Pacific

Johnson & Johnson, together with advocates and experts, came together to discuss and align on how best to tackle the tuberculosis (TB) crisis in the Asia-Pacific region, with the WHO Southeast Asia region witnessing the largest number of new TB cases globally. Over two days on 30 November and 7 December, Johnson & Johnson, together […]

thaipr.net

14 ธ.ค. 64

The innovative software “CAAS vFFR” by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization

Pie Medical Imaging (“PMI”), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning ofFASTIII, a multicenter randomized clinical trial which will investigate the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. The FASTIII trial, that is led by Dr. Joost Daemen (cardiologist at the Thoraxcenter at the Erasmus…

thaipr.net

13 ธ.ค. 64

New therapeutic approach against SARS-CoV-2 successfully tested

– Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARS-CoV-2 virus in human cells. – The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells. – Preclinical testing of […]

thaipr.net

13 ธ.ค. 64

CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies

Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment or applying a dose escalation schedule of neratinib associated with loperamide (as necessary) at treatment initiation over two-weeks reduces the incidence, severity, and duration of neratinib-associated grade 3 […]

thaipr.net

13 ธ.ค. 64
1 … 43 44 45 46 47 … 73

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.